Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1319)	4/24/1999 2:02:00 AM
From: tuck	Read Replies (1) \| Respond to of 1432

Post Script: the article notes that the $29 million market figure is for 1997 and was supplied by a market research firm called IMS. I've just emailed the person at Baxter who last responded to my email. I sent him a copy of the Gensia press release that had Michael Cannon, Gensia's president, mention HetaStarch's ANDA approval in connection with a distibution agreement with Baxter. It will be interesting to get the response to that one! It could be I got it backwards, and that Gensia is marketing Baxter stuff. But why have we seen no mention of HetaStarch in Gensia's recent quarterlies or 10-Ks? This isn't the first time a Gensia product has flopped, but something doesn't add up. Cheers, Tuck